CRISPR-Cas CLINICAL TRIALS

All | TALEN | ZFN | MegaNuclease | megaTAL | CAS-CLOVER | Base Editor

Bacterial Infection

E. coli infections, (NCT05277350)
Sponsors:
SNIPR Biome

IND Enabling

Phase I

Phase II

Phase III

Urinary Tract Infections, UTI, (NCT04191148)

Open access

Sponsors:
Locus Biosciences

IND Enabling

Phase I

Phase II

Phase III

Blood

Beta-Thalassemia, BT, (NCT03728322)
Sponsors:
Allife Medical Science and Technology Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT03655678)
Sponsors:
Vertex Pharmaceuticals Inc.

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT04205435)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT04211480)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT03164135)
Sponsors:
Affiliated Hospital to Academy of Military Medical Sciences

IND Enabling

Phase I

Phase II

Phase III

Human Immunodeficiency Virus Infection, HIV, (NCT05143307)
Sponsors:
Excision BioTherapeutics

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (2018-001320-19)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT03745287)
Sponsors:
Vertex Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04443907)
Sponsors:
Novartis Pharmaceuticals

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04774536)
Sponsors:
Mark Walters, MD

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04819841)

Discontinued

Sponsors:
Graphite Bio Inc

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04853576)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle cell disease, SCD, (NCT05951205)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassaemia, TDT, (NCT04925206)
Sponsors:
EdiGene (GuangZhou) Inc.

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital

IND Enabling

Phase I

Phase II

Phase III

Cancer

Acute Myeloid Leukaemia, AML, (NCT04849910)
Sponsors:
Vor Biopharma

IND Enabling

Phase I

Phase II

Phase III

Acute Myeloid Leukaemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Advanced Hepatocellular Carcinoma, HCC, (NCT04417764)
Sponsors:
Central South University

IND Enabling

Phase I

Phase II

Phase III

Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies, (NCT03044743)
Sponsors:
Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT03232619)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

B-cell Non-Hodgkin lymphoma, NHL, (NCT04213469)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Castrate-Resistant Prostate Cancer, CRPC, (NCT04768608)
Sponsors:
Zhejiang University

IND Enabling

Phase I

Phase II

Phase III

Diffuse Large B-cell Lymphoma, DLBCL, (NCT04026100)
Sponsors:
The First Affiliated Hospital of Nanjing Medical University

IND Enabling

Phase I

Phase II

Phase III

Epithelial Ovarian Cancer, EOC, (NCT05617755)
Sponsors:
Arsenal Biosciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Esophageal Cancer, (NCT03081715)
Sponsors:
Hangzhou Cancer Hospital

IND Enabling

Phase I

Phase II

Phase III

Gastro-Intestinal Cancer, GI, (NCT04426669)
Sponsors:
Intima Bioscience, Inc.

IND Enabling

Phase I

Phase II

Phase III

Human papillomavirus (HPV)-Related Cervical Cancer, (NCT03057912)
Sponsors:
First Affiliated Hospital, Sun Yat-Sen University

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT03399448)
Sponsors:
University of Pennsylvania

IND Enabling

Phase I

Phase II

Phase III

Multiple Myeloma, MM, (NCT05069935)
Sponsors:
Fate Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Muscle-Invasive Bladder Cancer, MIBC, (NCT02863913)
Sponsors:
Peking University

IND Enabling

Phase I

Phase II

Phase III

Non-small Cell Lung Cancer, NSCLC, (NCT02793856)
Sponsors:
Sichuan University

IND Enabling

Phase I

Phase II

Phase III

Non-small Cell Lung Cancer, NSCLC, (NCT03525782)
Sponsors:
First Affiliated Hospital of Guangdong Pharmaceutical University

IND Enabling

Phase I

Phase II

Phase III

Prostate Cancer, (NCT03525652)
Sponsors:
The First Affiliated Hospital of Guangdong Pharmaceutical University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Acute Myeloid Leukaemia, AML, (NCT05949125)
Sponsors:
AvenCell Europe GmbH

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Acute Myeloid Leukaemia, AML, and Multiple Myeloma, MM, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06128044)
Sponsors:
Caribou Biosciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B cell Malignancies, (NCT04227015)
Sponsors:
Zhejiang University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (2019-003462-40)
Sponsors:
Great Ormond Street Hospital for Children NHS Trust

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT04154709)
Sponsors:
Xuzhou Medical University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT04557436)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies (NCT03398967)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (2018-003916-38)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies, (NCT03166878)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT03298828)
Sponsors:
Third Military Medical University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT04035434)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT04037566)
Sponsors:
Xijing Hospital, The Fourth Military Medical University

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies, (NCT04629729)
Sponsors:
Fate Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Malignancies, (NCT04933825)
Sponsors:
EdiGene Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies, (NCT05643742)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Haematopoietic Malignancies, (NCT04767308)
Sponsors:
Huazhong University of Science and Technology

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT03492268)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT03752541)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT04244656)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT05182073)
Sponsors:
Fate Therapeutics Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT05722418)
Sponsors:
Caribou Biosciences

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Renal Cell Carcinoma, RCC, (NCT04438083)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Solid Tumors, (NCT05795595)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory T-Cell Lymphoma, (NCT04502446)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Solid Tumor Adult, (NCT03545815)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Solid Tumor, Adult, (NCT03747965)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Solid Tumor, Adult, (NCT04976218)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

Solid Tumors, (NCT04842812)
Sponsors:
Second Affiliated Hospital of Guangzhou Medical University

IND Enabling

Phase I

Phase II

Phase III

Solid Tumors, (NCT05395052)
Sponsors:
Fate Therapeutics

IND Enabling

Phase I

Phase II

Phase III

T-Cell Acute Lymphoblastic Leukaemia, T-ALL, (ChiCTR1900025311)
Sponsors:
Xinqiao Hospital of Chongqing, Second Affiliated Hospital of the Army Medical University, Hematology Department

IND Enabling

Phase I

Phase II

Phase III

T-Cell Acute Lymphoblastic Leukaemia, T-ALL, (ISRCTN15323014)
Sponsors:
Great Ormond Street Hospital

IND Enabling

Phase I

Phase II

Phase III

T-cell Acute Lymphoblastic Leukaemia, T-ALL, (NCT03690011)
Sponsors:
Baylor College of Medicine

IND Enabling

Phase I

Phase II

Phase III

T-Cell Lymphoblastic Leukaemia and Lymphoma, (NCT04264078)
Sponsors:
Xinqiao Hospital of Chongqing

IND Enabling

Phase I

Phase II

Phase III

Eye

Herpes Simplex Virus Refractory Keratitis, (NCT04560790)
Sponsors:
Shanghai BDgene Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Leber Congenital Amaurosis, LCA, (NCT03872479)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Neovascular Age-related Macular Degeneration, nAMD, (NCT06031727)
Sponsors:
HuidaGene Therapeutics Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Retinitis Pigmentosa, RP, (NCT05805007)
Sponsors:
Peking University Third Hospital

IND Enabling

Phase I

Phase II

Phase III

Metabolic Disorders

Phenylketonuria, PKU, (NCT05222178)
Sponsors:
Homology Medicines

IND Enabling

Phase I

Phase II

Phase III

Type 1 Diabetes, T1D, (NCT05210530)
Sponsors:
CRISPR Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Other Genetic Conditions

Limb Girdle Muscular Dystrophy, LGMD, (NCT05588401)
Sponsors:
Simone Spuler, MD

IND Enabling

Phase I

Phase II

Phase III

Transthyretin Amyloidosis, ATTR, (NCT04601051)
Sponsors:
Intellia Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Transthyretin Amyloidosis, ATTR, (NCT05697861)
Sponsors:
Intellia Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Transthyretin Amyloidosis, ATTR, (NCT06128629)
Sponsors:
Intellia Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Search CRISPR Medicine